NMD Pharma A/S: Financial statements 2022
CVR: 36899069
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2022. In 2022, the company reported a gross profit of EUR -9,480,436 and a net result of EUR -12,323,989 compared with EUR -13,614,082 the year before. Equity in the 2022 report amounted to EUR 25,132,967. The solvency ratio was 92.6%. The company had 26 employees in the financial year.
- Gross Profit
- EUR -9,480,436
- Profit/Loss
- EUR -12,323,989
- Equity
- EUR 25,132,967
- Total Assets
- EUR 27,138,564
- Employees
- 26
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -9.5 mio. EUR | -12.3 mio. EUR | 25.1 mio. EUR | 26 |
| 2021 | - | -11 mio. EUR | -13.6 mio. EUR | 2.6 mio. EUR | 26 |
| 2020 | - | -7.9 mio. EUR | -9.9 mio. EUR | 9.2 mio. EUR | 22 |
| 2019 | - | -7.1 mio. EUR | -8.5 mio. EUR | 140 t. EUR | 17 |
| 2018 | - | -4.7 mio. EUR | -5.5 mio. EUR | 88 t. EUR | 14 |
Official annual report
Keep an eye on NMD Pharma A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of December 15, 2022, Michael Thomas Heffernan has joined the board of directors of NMD Pharma A/S.
As of December 15, 2022, Patrick Volkert Jozef Johannes Vink has left the board of directors of NMD Pharma A/S.
NMD Pharma A/S has published its annual report for 2021. Gross profit came to DKK -11,029,051, and the net result was DKK -13,614,082.
As of February 4, 2022, Sabine Kohar Dandiguian has joined the board of directors of NMD Pharma A/S.
As of February 4, 2022, David William Evans has joined the board of directors of NMD Pharma A/S.
As of February 4, 2022, Monique Claude Schiersing has left the board of directors of NMD Pharma A/S.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.